

Ann-Mari Svennerholm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10704342/publications.pdf>

Version: 2024-02-01

205
papers

10,198
citations

30070

54
h-index

46799

89
g-index

210
all docs

210
docs citations

210
times ranked

5848
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants. <i>Vaccine</i> , 2022, 40, 380-389.	3.8	17
2	A Systems Biology Approach Identifies B Cell Maturation Antigen (BCMA) as a Biomarker Reflecting Oral Vaccine Induced IgA Antibody Responses in Humans. <i>Frontiers in Immunology</i> , 2021, 12, 647873.	4.8	6
3	Long-read-sequenced reference genomes of the seven major lineages of enterotoxigenic <i>Escherichia coli</i> (ETEC) circulating in modern time. <i>Scientific Reports</i> , 2021, 11, 9256.	3.3	12
4	Enterotoxigenic <i>Escherichia coli</i> (ETEC) vaccines: Priority activities to enable product development, licensure, and global access. <i>Vaccine</i> , 2021, 39, 4266-4277.	3.8	60
5	Mucosal Immune Responses Against an Oral Enterotoxigenic <i>Escherichia coli</i> Vaccine Evaluated in Clinical Trials. <i>Journal of Infectious Diseases</i> , 2021, 224, S821-S828.	4.0	15
6	Oral Vaccines for Enterotoxigenic <i>Escherichia coli</i> . , 2020, , 563-578.		2
7	Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial. <i>Vaccine</i> , 2020, 38, 655-662.	3.8	6
8	Safety and immunogenicity of the oral, inactivated, enterotoxigenic <i>Escherichia coli</i> vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 208-219.	9.1	81
9	Clinical aspects of heat-labile and heat-stable toxin-producing enterotoxigenic <i>Escherichia coli</i> : A prospective study among Finnish travellers. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101855.	3.0	16
10	Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and <i>Shigella</i> infections, and their potential to serve as correlates of protection in vaccine development. <i>Vaccine</i> , 2019, 37, 4787-4793.	3.8	15
11	Colonization factors among enterotoxigenic <i>Escherichia coli</i> isolates from children with moderate-to-severe diarrhea and from matched controls in the Global Enteric Multicenter Study (GEMS). <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007037.	3.0	68
12	Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses. <i>Vaccine</i> , 2019, 37, 5645-5656.	3.8	48
13	Assessing antigen specific HLA-DR+ antibody secreting cell (DR+ASC) responses in whole blood in enteric infections using an ELISPOT technique. <i>Microbes and Infection</i> , 2018, 20, 122-129.	1.9	0
14	Glyco-engineered cell line and computational docking studies reveals enterotoxigenic <i>Escherichia coli</i> CFA/I fimbriae bind to Lewis a glycans. <i>Scientific Reports</i> , 2018, 8, 11250.	3.3	7
15	Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. <i>Vaccine</i> , 2017, 35, 321-328.	3.8	20
16	Surface expression of <i>Helicobacter pylori</i> HpaA adhesion antigen on <i>Vibrio cholerae</i> , enhanced by co-expressed enterotoxigenic <i>Escherichia coli</i> fimbrial antigens. <i>Microbial Pathogenesis</i> , 2017, 105, 177-184.	2.9	18
17	Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> (ETEC) vaccine ETVAX. <i>Vaccine</i> , 2017, 35, 3966-3973.	3.8	36
18	Identification and characterization of the novel colonization factor CS30 based on whole genome sequencing in enterotoxigenic <i>Escherichia coli</i> (ETEC). <i>Scientific Reports</i> , 2017, 7, 12514.	3.3	24

#	ARTICLE	IF	CITATIONS
19	FUT2 non-secretor status is associated with altered susceptibility to symptomatic enterotoxigenic <i>Escherichia coli</i> infection in Bangladeshis. <i>Scientific Reports</i> , 2017, 7, 10649.	3.3	30
20	Gastric expression of IL-17A and IFN γ in <i>Helicobacter pylori</i> infected individuals is related to symptoms. <i>Cytokine</i> , 2017, 99, 30-34.	3.2	27
21	Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> vaccine. <i>Vaccine</i> , 2016, 34, 3132-3140.	3.8	36
22	Identification of new heat-stable (STa) enterotoxin allele variants produced by human enterotoxigenic <i>Escherichia coli</i> (EPEC). <i>International Journal of Medical Microbiology</i> , 2016, 306, 586-594.	3.6	36
23	Enumeration of Gut-Homing γ T γ 27-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic <i>Escherichia coli</i> - and <i>Vibrio cholerae</i> -Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique. <i>Vaccine Journal</i> , 2016, 23, 27-36.	3.1	10
24	Stability of the Encoding Plasmids and Surface Expression of CS6 Differs in Enterotoxigenic <i>Escherichia coli</i> (EPEC) Encoding Different Heat-Stable (ST) Enterotoxins (STh and STp). <i>PLoS ONE</i> , 2016, 11, e0152899.	2.5	10
25	<i>Helicobacter pylori</i> Infection of the Gastric Mucosa. , 2015, , 985-1001.		4
26	Implications of enterotoxigenic <i>Escherichia coli</i> genomics for vaccine development. <i>Expert Review of Vaccines</i> , 2015, 14, 551-560.	4.4	16
27	A comparison of seasonal variations in rotavirus antibodies in the breast milk of Swedish and Bangladeshi mothers. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2015, 104, 247-251.	1.5	11
28	Allele Variants of Enterotoxigenic <i>Escherichia coli</i> Heat-Labile Toxin Are Globally Transmitted and Associated with Colonization Factors. <i>Journal of Bacteriology</i> , 2015, 197, 392-403.	2.2	23
29	Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> (EPEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. <i>Vaccine</i> , 2014, 32, 7077-7084.	3.8	117
30	Antigen-Specific Memory B-cell Responses to Enterotoxigenic <i>Escherichia coli</i> Infection in Bangladeshi Adults. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2822.	3.0	25
31	Shift in Phenotypic Characteristics of Enterotoxigenic <i>Escherichia coli</i> (EPEC) Isolated from Diarrheal Patients in Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3031.	3.0	43
32	Pathogenicity and Phenotypic Characterization of Enterotoxigenic <i>Escherichia coli</i> Isolates from a Birth Cohort of Children in Rural Egypt. <i>Journal of Clinical Microbiology</i> , 2014, 52, 587-591.	3.9	16
33	Response on letter by Arya et al.: "Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh." <i>Vaccine</i> , 2014, 32, 4014.	3.8	0
34	Identification of enterotoxigenic <i>Escherichia coli</i> (EPEC) clades with long-term global distribution. <i>Nature Genetics</i> , 2014, 46, 1321-1326.	21.4	192
35	Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh. <i>Vaccine</i> , 2014, 32, 1055-1060.	3.8	29
36	Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children. <i>Vaccine</i> , 2013, 31, 647-652.	3.8	25

#	ARTICLE	IF	CITATIONS
37	Immune responses and protection in children in developing countries induced by oral vaccines. <i>Vaccine</i> , 2013, 31, 452-460.	3.8	86
38	Immune Responses Against <i>Helicobacter pylori</i> in Gastric Cancer Patients and in Risk Groups for Gastric Cancer. <i>Helicobacter</i> , 2013, 18, 73-82.	3.5	13
39	Different kinetics of circulating antibody-secreting cell responses after primary and booster oral immunizations: A tool for assessing immunological memory. <i>Vaccine</i> , 2013, 31, 3035-3038.	3.8	32
40	Prevalence, seasonality and severity of disease caused by pathogenic <i>Escherichia coli</i> in children with diarrhoea in Bolivia. <i>Journal of Medical Microbiology</i> , 2013, 62, 1697-1706.	1.8	28
41	Molecular Characterization of Enterotoxigenic <i>Escherichia coli</i> Isolates Recovered from Children with Diarrhea during a 4-Year Period (2007 to 2010) in Bolivia. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1219-1225.	3.9	25
42	Recent progress toward an enterotoxigenic <i>Escherichia coli</i> vaccine. <i>Expert Review of Vaccines</i> , 2012, 11, 495-507.	4.4	94
43	Vaccines against mucosal infections. <i>Current Opinion in Immunology</i> , 2012, 24, 343-353.	5.5	132
44	Strategies to overexpress enterotoxigenic <i>Escherichia coli</i> (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates. <i>Applied Microbiology and Biotechnology</i> , 2012, 93, 2291-2300.	3.6	29
45	Expression of Colonization Factor CS5 of Enterotoxigenic <i>Escherichia coli</i> (ETEC) Is Enhanced In Vivo and by the Bile Component Na Glycocholate Hydrate. <i>PLoS ONE</i> , 2012, 7, e35827.	2.5	35
46	Enterotoxins, colonization factors, serotypes and antimicrobial resistance of enterotoxigenic <i>Escherichia coli</i> (ETEC) strains isolated from hospitalized children with diarrhea in Bolivia. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 132-137.	0.6	39
47	Construction of a non-toxigenic <i>Escherichia coli</i> oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. <i>Vaccine</i> , 2011, 29, 8863-8869.	3.8	27
48	Impaired IFN- γ production after stimulation with bacterial components by natural killer cells from gastric cancer patients. <i>Experimental Cell Research</i> , 2011, 317, 849-858.	2.6	23
49	Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic <i>Escherichia coli</i> Vaccines. <i>Vaccine Journal</i> , 2011, 18, 1719-1727.	3.1	76
50	Impact of Rapid Urbanization on the Rates of Infection by <i>Vibrio cholerae</i> O1 and Enterotoxigenic <i>Escherichia coli</i> in Dhaka, Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e999.	3.0	62
51	Enterotoxins, colonization factors, serotypes and antimicrobial resistance of enterotoxigenic <i>Escherichia coli</i> (ETEC) strains isolated from hospitalized children with diarrhea in Bolivia. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 132-137.	0.6	13
52	From cholera to enterotoxigenic <i>Escherichia coli</i> (ETEC) vaccine development. <i>Indian Journal of Medical Research</i> , 2011, 133, 188-96.	1.0	37
53	Construction and expression of immunogenic hybrid enterotoxigenic <i>Escherichia coli</i> CFA/II and CS2 colonization fimbriae for use in vaccines. <i>Applied Microbiology and Biotechnology</i> , 2010, 87, 1355-1365.	3.6	14
54	Detection of the CS20 colonization factor antigen in diffuse-adhering <i>Escherichia coli</i> strains. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 60, 186-189.	2.7	8

#	ARTICLE	IF	CITATIONS
55	Immune Responses to <i>Helicobacter pylori</i> Infection in Bangladeshi Children during Their First Two Years of Life and the Association between Maternal Antibodies and Onset of Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, 1676-1684.	4.0	21
56	Concomitant Enterotoxigenic <i>Escherichia coli</i> Infection Induces Increased Immune Responses to <i>Vibrio cholerae</i> O1 Antigens in Patients with Cholera in Bangladesh. <i>Infection and Immunity</i> , 2010, 78, 2117-2124.	2.2	20
57	CD8 ⁺ Natural Killer Cells Are Greatly Enriched in the Human Gastrointestinal Tract and Have the Capacity to Respond to Bacteria. <i>Journal of Innate Immunity</i> , 2010, 2, 294-302.	3.8	17
58	Enterotoxigenic <i>Escherichia coli</i> Multilocus Sequence Types in Guatemala and Mexico. <i>Emerging Infectious Diseases</i> , 2010, 16, 143-145.	4.3	13
59	Over-expression of major colonization factors of enterotoxigenic <i>Escherichia coli</i> , alone or together, on non-toxigenic <i>E. coli</i> bacteria. <i>Vaccine</i> , 2010, 28, 6977-6984.	3.8	22
60	Sulfatide Recognition by Colonization Factor Antigen CS6 from Enterotoxigenic <i>Escherichia coli</i> . <i>PLoS ONE</i> , 2009, 4, e4487.	2.5	45
61	Failure To Detect <i>Helicobacter pylori</i> DNA in Drinking and Environmental Water in Dhaka, Bangladesh, Using Highly Sensitive Real-Time PCR Assays. <i>Applied and Environmental Microbiology</i> , 2009, 75, 3039-3044.	3.1	46
62	Children with the Le(a+b ⁻) Blood Group Have Increased Susceptibility to Diarrhea Caused by Enterotoxigenic <i>Escherichia coli</i> Expressing Colonization Factor I Group Fimbriae. <i>Infection and Immunity</i> , 2009, 77, 2059-2064.	2.2	37
63	Development of Multiplex PCR Assays for Detection of Enterotoxigenic <i>Escherichia coli</i> Colonization Factors and Toxins. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1218-1220.	3.9	85
64	Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. <i>Clinical Immunology</i> , 2009, 131, 463-471.	3.2	24
65	FOXP3 ⁺ CD4 ⁺ T _H 17 Cell Numbers Increase in Areas of Duodenal Gastric Metaplasia and are Associated to CD4 ⁺ T _H 1 Cell Aggregates in the Duodenum of <i>Helicobacter pylori</i> -infected Duodenal Ulcer Patients. <i>Helicobacter</i> , 2009, 14, 192-201.	3.5	23
66	Presence of High Numbers of Transcriptionally Active <i>Helicobacter pylori</i> in Vomitus from Bangladeshi Patients Suffering from Acute Gastroenteritis. <i>Helicobacter</i> , 2009, 14, 237-247.	3.5	20
67	Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. <i>Vaccine</i> , 2009, 27, 1433-1439.	3.8	57
68	Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent <i>V. cholerae</i> O1/O139 whole cell cholera vaccine: Comparison with other mucosal and systemic responses. <i>Vaccine</i> , 2009, 27, 1386-1392.	3.8	30
69	Infection by <i>Helicobacter Pylori</i> in Bangladeshi Children From Birth to Two Years. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 79-85.	2.0	42
70	Comparison of mucosal B- and T-cell responses in <i>Helicobacter pylori</i> -infected subjects in a developing and a developed country. <i>FEMS Immunology and Medical Microbiology</i> , 2008, 54, 70-79.	2.7	10
71	Vaccines against enterotoxigenic <i>Escherichia coli</i> . <i>Expert Review of Vaccines</i> , 2008, 7, 795-804.	4.4	107
72	Mutations in the periplasmic chaperone leading to loss of surface expression of the colonization factor CS6 in enterotoxigenic <i>Escherichia coli</i> (ETEC) clinical isolates. <i>Microbial Pathogenesis</i> , 2008, 44, 246-254.	2.9	17

#	ARTICLE	IF	CITATIONS
73	Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae. <i>Vaccine</i> , 2008, 26, 743-752.	3.8	31
74	Role of different genes in the CS6 operon for surface expression of Enterotoxigenic Escherichia coli colonization factor CS6. <i>Vaccine</i> , 2008, 26, 5373-5380.	3.8	24
75	Determinants of Responses to Oral Vaccines in Developing Countries. <i>Annales Nestle</i> , 2008, 66, 71-79.	0.1	16
76	Determinants des réponses aux vaccins oraux dans les pays en développement. <i>Annales Nestle [Ed Française]</i> , 2008, 66, 71-80.	0.0	6
77	Determinantes de las respuestas a vacunas orales en países en vías de desarrollo. <i>Annales Nestlé</i> (Ed) Tj ETQq1 1 0.784314 rgBT /Dv	0.1	0
78	Shifting Prevalence of Major Diarrheal Pathogens in Patients Seeking Hospital Care during Floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 708-714.	1.4	101
79	Mucosal Immune Responses Against Enterotoxigenic Escherichia coli [ETEC] in Humans. , 2008, , 153-171.		0
80	Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 708-14.	1.4	55
81	Mucosal and Systemic Immune Responses in Patients with Diarrhea Due to CS6-Expressing Enterotoxigenic Escherichia coli. <i>Infection and Immunity</i> , 2007, 75, 2269-2274.	2.2	27
82	Disease Burden Due to Enterotoxigenic Escherichia coli in the First 2 Years of Life in an Urban Community in Bangladesh. <i>Infection and Immunity</i> , 2007, 75, 3961-3968.	2.2	180
83	Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses. <i>Vaccine</i> , 2007, 25, 2591-2598.	3.8	60
84	Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. <i>Vaccine</i> , 2007, 25, 4392-4400.	3.8	102
85	Progress in vaccine development against Helicobacter pylori. <i>FEMS Immunology and Medical Microbiology</i> , 2007, 50, 146-156.	2.7	34
86	The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. <i>Clinical Immunology</i> , 2007, 125, 205-213.	3.2	30
87	Characterization of the Outer Membrane Protein Profile from Disease-Related Helicobacter pylori Isolates by Subcellular Fractionation and Nano-LC FT-ICR MS Analysis. <i>Journal of Proteome Research</i> , 2006, 5, 3197-3204.	3.7	61
88	B cells pulsed with Helicobacter pylori antigen efficiently activate memory CD8+ T cells from H. pylori-infected individuals. <i>Clinical Immunology</i> , 2006, 118, 284-291.	3.2	23
89	Enterotoxigenic Escherichia coli colonization factor types collected from 1997 to 2001 in US military personnel during operation Bright Star in northern Egypt. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 55, 9-12.	1.8	24
90	Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: Dosing studies in different age groups. <i>Vaccine</i> , 2006, 24, 1726-1733.	3.8	55

#	ARTICLE	IF	CITATIONS
91	Breast Milk Reduces the Risk of Illness in Children of Mothers With Cholera. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 1163-1166.	2.0	34
92	Dendritic cells express CCR7 and migrate in response to CCL19 (MIP-3 β) after exposure to <i>Helicobacter pylori</i> . <i>Microbes and Infection</i> , 2006, 8, 841-850.	1.9	36
93	In vivo expression of the heat stable (<i>estA</i>) and heat labile (<i>eltB</i>) toxin genes of enterotoxigenic <i>Escherichia coli</i> (ETEC). <i>Microbes and Infection</i> , 2006, 8, 2797-2802.	1.9	25
94	The Major Subunit, CfaB, of Colonization Factor Antigen I from Enterotoxigenic <i>Escherichia coli</i> Is a Glycosphingolipid Binding Protein. <i>Infection and Immunity</i> , 2006, 74, 3488-3497.	2.2	70
95	Homologous and Cross-Reactive Immune Responses to Enterotoxigenic <i>Escherichia coli</i> Colonization Factors in Bangladeshi Children. <i>Infection and Immunity</i> , 2006, 74, 4512-4518.	2.2	27
96	Enterotoxigenic <i>Escherichia coli</i> with STh and STp Genotypes Is Associated with Diarrhea Both in Children in Areas of Endemicity and in Travelers. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3872-3877.	3.9	65
97	Cholera Due to Altered El Tor Strains of <i>Vibrio cholerae</i> O1 in Bangladesh. <i>Journal of Clinical Microbiology</i> , 2006, 44, 4211-4213.	3.9	222
98	HpaA Is Essential for <i>Helicobacter pylori</i> Colonization in Mice. <i>Infection and Immunity</i> , 2006, 74, 920-926.	2.2	70
99	Engineered bacterial toxin vaccines and adjuvants. , 2006, , 1008-1018.		0
100	<i>Helicobacter pylori</i> induce neutrophil transendothelial migration: Role of the bacterial HP-NAP. <i>FEMS Microbiology Letters</i> , 2005, 249, 95-103.	1.8	76
101	Enterotoxigenic <i>Escherichia coli</i> and <i>Vibrio cholerae</i> Diarrhea, Bangladesh, 2004. <i>Emerging Infectious Diseases</i> , 2005, 11, 1104-1107.	4.3	123
102	Mucosal FOXP3-Expressing CD4 ⁺ CD25 ^{high} Regulatory T Cells in <i>Helicobacter pylori</i> -Infected Patients. <i>Infection and Immunity</i> , 2005, 73, 523-531.	2.2	246
103	Serologic Correlates of Protection against Enterotoxigenic <i>Escherichia coli</i> Diarrhea. <i>Journal of Infectious Diseases</i> , 2005, 191, 562-570.	4.0	60
104	Reduction in Capsular Content and Enhanced Bacterial Susceptibility to Serum Killing of <i>Vibrio cholerae</i> O139 Associated with the 2002 Cholera Epidemic in Bangladesh. <i>Infection and Immunity</i> , 2005, 73, 6577-6583.	2.2	22
105	Enterotoxigenic <i>Escherichia coli</i> Isolated from Surface Water in Urban and Rural Areas of Bangladesh. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3582-3583.	3.9	52
106	<i>Helicobacter pylori</i> -Specific CD4 ⁺ T Cells Home to and Accumulate in the Human <i>Helicobacter pylori</i> -Infected Gastric Mucosa. <i>Infection and Immunity</i> , 2005, 73, 5612-5619.	2.2	83
107	Natural Killer Cells and <i>Helicobacter pylori</i> Infection: Bacterial Antigens and Interleukin-12 Act Synergistically To Induce Gamma Interferon Production. <i>Infection and Immunity</i> , 2005, 73, 1482-1490.	2.2	61
108	Enterotoxigenic <i>Escherichia coli</i> in Developing Countries: Epidemiology, Microbiology, Clinical Features, Treatment, and Prevention. <i>Clinical Microbiology Reviews</i> , 2005, 18, 465-483.	13.6	804

#	ARTICLE	IF	CITATIONS
109	Mucosal Immunity to Bacteria. , 2005, , 783-797.		7
110	Detection of Antibodies to Toxin-Coregulated Pili in Sera from Cholera Patients. Infection and Immunity, 2004, 72, 1824-1827.	2.2	13
111	Phenotypic Profiles of Enterotoxigenic Escherichia coli Associated with Early Childhood Diarrhea in Rural Egypt. Journal of Clinical Microbiology, 2004, 42, 5588-5595.	3.9	87
112	Progress in enteric vaccine development. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 421-445.	2.4	72
113	Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine, 2004, 22, 984-990.	3.8	64
114	<i>Helicobacter pylori</i> inflammation, immunity and vaccines. Helicobacter, 2003, 8, 31-35.	3.5	14
115	Priming and expression of immune responses in the gastric mucosa. Microbes and Infection, 2003, 5, 731-739.	1.9	12
116	Prospects for a mucosally-administered vaccine against <i>Helicobacter pylori</i> . Vaccine, 2003, 21, 347-353.	3.8	17
117	Safety and immunogenicity of an oral, inactivated enterotoxigenic <i>Escherichia coli</i> plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine, 2003, 21, 2394-2403.	3.8	57
118	<i>Helicobacter pylori</i> Specific CD4 ⁺ CD25 ^{high} Regulatory T Cells Suppress Memory T-Cell Responses to <i>H. pylori</i> in Infected Individuals. Infection and Immunity, 2003, 71, 1755-1762.	2.2	288
119	High Disease Burden of Diarrhea Due to Enterotoxigenic <i>Escherichia coli</i> among Rural Egyptian Infants and Young Children. Journal of Clinical Microbiology, 2003, 41, 4862-4864.	3.9	78
120	T- and B-Cell Immune Responses of Patients Who Had Undergone Colectomies to Oral Administration of <i>Salmonella enterica</i> Serovar Typhi Ty21a Vaccine. Vaccine Journal, 2003, 10, 426-430.	3.1	17
121	Oral Immunization with a <i>Salmonella enterica</i> Serovar Typhi Vaccine Induces Specific Circulating Mucosa-Homing CD4 ⁺ and CD8 ⁺ T Cells in Humans. Infection and Immunity, 2002, 70, 5622-5627.	2.2	97
122	Introductory evaluation of an oral, killed whole cell enterotoxigenic <i>Escherichia coli</i> plus cholera toxin B subunit vaccine in Egyptian infants. Pediatric Infectious Disease Journal, 2002, 21, 322-330.	2.0	64
123	Antigenic variation within the subunit protein of members of the colonization factor antigen I group of fimbrial proteins in human enterotoxigenic <i>Escherichia coli</i> . International Journal of Medical Microbiology, 2002, 292, 43-50.	3.6	21
124	Increased Levels of Inflammatory Mediators in Children and Adults Infected with <i>Vibrio cholerae</i> O1 and O139. Vaccine Journal, 2002, 9, 221-229.	3.1	59
125	The expression of the <i>Helicobacter pylori</i> genes ureA and nap1 is higher in vivo than in vitro as measured by quantitative competitive reverse transcriptase-PCR. FEMS Immunology and Medical Microbiology, 2002, 32, 219-226.	2.7	13
126	Flow cytometric analysis of the localization of <i>Helicobacter pylori</i> antigens during different growth phases. FEMS Immunology and Medical Microbiology, 2001, 30, 173-179.	2.7	27

#	ARTICLE	IF	CITATIONS
127	Dose-Dependent Circulating Immunoglobulin A Antibody-Secreting Cell and Serum Antibody Responses in Swedish Volunteers to an Oral Inactivated Enterotoxigenic Escherichia coli Vaccine. <i>Vaccine Journal</i> , 2001, 8, 424-428.	2.6	30
128	Induction and Distribution of Intestinal Immune Responses after Administration of Recombinant Cholera Toxin B Subunit in the Ileal Pouches of Colectomized Patients. <i>Infection and Immunity</i> , 2001, 69, 3466-3471.	2.2	8
129	Induction of Systemic Antifimbria and Antitoxin Antibody Responses in Egyptian Children and Adults by an Oral, Killed Enterotoxigenic Escherichia coli plus Cholera Toxin B Subunit Vaccine. <i>Infection and Immunity</i> , 2001, 69, 2853-2857.	2.2	46
130	Flow cytometric analysis of the localization of Helicobacter pylori antigens during different growth phases. <i>FEMS Immunology and Medical Microbiology</i> , 2001, 30, 173-179.	2.7	1
131	Development of a new method for the determination of immune responses in the human stomach. <i>Journal of Immunological Methods</i> , 2000, 234, 51-59.	1.4	20
132	Different Helicobacter pylori Strains Colonize the Antral and Duodenal Mucosa of Duodenal Ulcer Patients. <i>Helicobacter</i> , 2000, 5, 69-78.	3.5	17
133	Characterization of Enterotoxigenic Escherichia coli Strains in Patients with Travelers' Diarrhea Acquired in Guadalajara, Mexico, 1992-1997. <i>Journal of Infectious Diseases</i> , 2000, 181, 779-782.	4.0	46
134	Safety and Immunogenicity of Two Different Lots of the Oral, Killed Enterotoxigenic Escherichia coli -Cholera Toxin B Subunit Vaccine in Israeli Young Adults. <i>Infection and Immunity</i> , 2000, 68, 4492-4497.	2.2	27
135	Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. <i>Vaccine</i> , 2000, 18, 2704-2712.	3.8	59
136	Etiology of Travelers'™ Diarrhea on a Caribbean Island. <i>Journal of Travel Medicine</i> , 2000, 7, 15-18.	3.0	22
137	Double-Blind, Randomized, Placebo Controlled Pilot Study Evaluating Efficacy and Reactogenicity of an Oral ETEC B-Subunit-Inactivated Whole Cell Vaccine against Travelers'™ Diarrhea (Preliminary) Tj ETQq1 1 0.7843 14 rgBj6/Overlo		
138	Prevalence of Toxin Types and Colonization Factors in Enterotoxigenic Escherichia coli Isolated during a 2-Year Period from Diarrheal Patients in Bangladesh. <i>Journal of Clinical Microbiology</i> , 2000, 38, 27-31.	3.9	173
139	Differences in Surface-Exposed Antigen Expression between Helicobacter pylori Strains Isolated from Duodenal Ulcer Patients and from Asymptomatic Subjects. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3436-3441.	3.9	38
140	Mechanisms involved in Helicobacter pylori induced duodenal ulcer disease: an overview. <i>World Journal of Gastroenterology</i> , 2000, 6, 619.	3.3	20
141	Intestinal Immune Responses in Patients Infected with Enterotoxigenic Escherichia coli and in Vaccinees. <i>Infection and Immunity</i> , 1999, 67, 6234-6241.	2.2	39
142	Prospective Cohort Study of Enterotoxigenic Escherichia coli Infections in Argentinean Children. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2829-2833.	3.9	50
143	Phenotypic Diversity of Enterotoxigenic Escherichia coli Strains from a Community-Based Study of Pediatric Diarrhea in Periurban Egypt. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2974-2978.	3.9	60
144	Antibodies against Helicobacter pylori in feces and saliva before and after eradication therapy. <i>Clinical Microbiology and Infection</i> , 1998, 4, 634-643.	6.0	2

#	ARTICLE	IF	CITATIONS
145	Safety and immunogenicity of an oral inactivated enterotoxigenic <i>Escherichia coli</i> vaccine. <i>Vaccine</i> , 1998, 16, 255-260.	3.8	93
146	Intestinal Immune Responses to an Inactivated Oral Enterotoxigenic <i>Escherichia coli</i> Vaccine and Associated Immunoglobulin A Responses in Blood. <i>Infection and Immunity</i> , 1998, 66, 3311-3316.	2.2	97
147	Immune Responses in Ileostomy Fluid and Serum after Oral Cholera Vaccination of Patients Colectomized because of Ulcerative Colitis. <i>Infection and Immunity</i> , 1998, 66, 3995-3999.	2.2	12
148	Antibody Responses in Humans against Coli Surface Antigen 6 of Enterotoxigenic <i>Escherichia coli</i> . <i>Infection and Immunity</i> , 1998, 66, 4507-4510.	2.2	12
149	Local and systemic immune responses in humans against <i>Helicobacter pylori</i> antigens from homologous and heterologous strains. <i>Microbial Pathogenesis</i> , 1997, 23, 285-296.	2.9	15
150	Binding of enterotoxigenic <i>Escherichia coli</i> to isolated enterocytes and intestinal mucus. <i>Microbial Pathogenesis</i> , 1997, 23, 335-346.	2.9	23
151	Monoclonal antibodies against fimbrial subunits of colonization factor antigen I (CFA/I) inhibit binding to human enterocytes and protect against enterotoxigenic <i>Escherichia coli</i> expressing heterologous colonization factors. <i>Microbial Pathogenesis</i> , 1996, 21, 35-45.	2.9	27
152	Binding of enterotoxigenic <i>Escherichia coli</i> expressing different colonization factors to tissue-cultured Caco-2 cells and to isolated human enterocytes. <i>Microbial Pathogenesis</i> , 1996, 21, 139-147.	2.9	25
153	Oral Vaccines against Cholera and Enterotoxigenic <i>Escherichia coli</i> Diarrhea. , 1996, , 241-253.		16
154	<i>Campylobacter jejuni/coli</i> and Enterotoxigenic <i>Escherichia coli</i> (ETEC) in Faeces from Children and Adults in Tanzania. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 589-593.	1.5	35
155	Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea. <i>Journal of Travel Medicine</i> , 1995, 2, 22-27.	3.0	83
156	Immunological response to <i>Vibrio cholerae</i> O1 infection and an oral cholera vaccine among Peruvians. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1995, 89, 542-545.	1.8	14
157	Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. <i>Vaccine</i> , 1994, 12, 1078-1082.	3.8	44
158	Colonization factor antigens (CFAs) of enterotoxigenic <i>Escherichia coli</i> can prime and boost immune responses against heterologous CFAs. <i>Microbial Pathogenesis</i> , 1994, 16, 131-139.	2.9	25
159	Induction and Assessment of Immunity at Enteromucosal Surfaces in Humans: Implications for Vaccine Development. <i>Clinical Infectious Diseases</i> , 1993, 16, S106-S116.	5.8	44
160	Induction of colonization factor antigen I (CFA/I) and coli surface antigen 4 (CS4) of enterotoxigenic <i>Escherichia coli</i> : relevance for vaccine production. <i>Vaccine</i> , 1993, 11, 221-226.	3.8	15
161	Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. <i>Vaccine</i> , 1993, 11, 1007-1012.	3.8	53
162	Intestinal antibody response after oral immunization with a prototype cholera B subunit antigen enterotoxigenic <i>Escherichia coli</i> vaccine. <i>Vaccine</i> , 1993, 11, 929-934.	3.8	78

#	ARTICLE	IF	CITATIONS
163	Mucosal Immunity: Implications for Vaccine Development. <i>Immunobiology</i> , 1992, 184, 157-179.	1.9	168
164	T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions. <i>Molecular Immunology</i> , 1992, 29, 1185-1190.	2.2	34
165	Safety and immunogenicity of an oral recombinant cholera B subunit whole cell vaccine in Swedish volunteers. <i>Vaccine</i> , 1992, 10, 130-132.	3.8	106
166	Enzyme-linked immunosorbent assay for determination of antibodies to <i>Vibrio cholerae</i> toxin coregulated pili. <i>Apmis</i> , 1992, 100, 1027-1032.	2.0	3
167	Epitope differences in toxin-coregulated pili produced by classical and El Tor <i>Vibrio cholerae</i> O1. <i>Microbial Pathogenesis</i> , 1991, 11, 179-188.	2.9	53
168	Presence of <i>cfaD</i> -homologous sequences and expression of coli surface antigen 4 on enterotoxigenic <i>Escherichia coli</i> ; relevance for diagnostic procedures. <i>Microbial Pathogenesis</i> , 1991, 11, 297-304.	2.9	13
169	Identification of a mannose-binding pilus on <i>Vibrio cholerae</i> El Tor. <i>Microbial Pathogenesis</i> , 1991, 11, 433-441.	2.9	114
170	A recombinant <i>Escherichia coli</i> heat-stable enterotoxin (STa) fusion protein eliciting anti-STa neutralizing antibodies. <i>FEMS Microbiology Letters</i> , 1991, 82, 271-278.	1.8	23
171	Production and characterization of monoclonal antibodies to <i>Vibrio cholerae</i> soluble haemagglutinin. <i>Apmis</i> , 1991, 99, 249-256.	2.0	5
172	Enterotoxin-producing bacteria isolated from Swedish travellers with diarrhoea. <i>Scandinavian Journal of Infectious Diseases</i> , 1991, 23, 473-479.	1.5	26
173	Expression of virulence factors by classical and El Tor <i>Vibrio cholerae</i> in vivo and in vitro. <i>FEMS Microbiology Ecology</i> , 1990, 7, 221-228.	2.7	1
174	Identification of asialo GM1 as a binding structure for <i>Escherichia coli</i> colonization factor antigens. <i>FEMS Microbiology Letters</i> , 1990, 72, 289-292.	1.8	10
175	Expression of virulence factors by classical and El Tor <i>Vibrio cholerae</i> in vivo and in vitro. <i>FEMS Microbiology Letters</i> , 1990, 74, 221-228.	1.8	22
176	Enhanced immunogenicity of recombinant peptide fusions containing multiple copies of a heterologous T helper epitope. <i>European Journal of Immunology</i> , 1990, 20, 1541-1545.	2.9	22
177	BREAST FEEDING AND THE RISK OF SEVERE CHOLERA IN RURAL BANGLADESHI CHILDREN. <i>American Journal of Epidemiology</i> , 1990, 131, 400-411.	3.4	77
178	Estimation of Symptomatic and Asymptomatic <i>Salmonella</i> Infections. <i>Scandinavian Journal of Infectious Diseases</i> , 1990, 22, 451-455.	1.5	28
179	Serum Antibody Responses to Bacterial Enteropathogens in Swedish Travellers to South-East Asia. <i>Scandinavian Journal of Infectious Diseases</i> , 1990, 22, 699-704.	1.5	3
180	Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. <i>Vaccine</i> , 1990, 8, 469-472.	3.8	36

#	ARTICLE	IF	CITATIONS
181	Expression of virulence factors by classical and El Tor <i>Vibrio cholerae</i> in vivo and in vitro. <i>FEMS Microbiology Letters</i> , 1990, 74, 221-228.	1.8	1
182	Mechanism of spontaneous loss of heat-stable toxin (STa) production in enterotoxigenic <i>Escherichia coli</i> . <i>Apmis</i> , 1989, 97, 436-440.	2.0	16
183	Development of oral vaccines against enterotoxinogenic <i>Escherichia coli</i> diarrhoea. <i>Vaccine</i> , 1989, 7, 196-198.	3.8	114
184	Mucosal Immunity in the Gastrointestinal Tract in Relation to ETEC Vaccine Development. <i>Progress in Vaccinology</i> , 1989, , 181-196.	0.7	1
185	Oral B Subunit-Whole Cell Vaccine Against Cholera: From Basic Research to Successful Field Trial. <i>Progress in Vaccinology</i> , 1989, , 119-130.	0.7	0
186	Synthesis on nontoxic, antibody-binding <i>Escherichia coli</i> heat-stable enterotoxin (STa) peptides. <i>FEMS Microbiology Letters</i> , 1988, 55, 23-28.	1.8	22
187	A Prospective Study of Serum Antibody Responses to Enterotoxinogenic <i>Escherichia coli</i> in Swedish Travellers. <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 69-75.	1.5	7
188	COLONIZATION, DIARRHOEA AND PROTECTIVE IMMUNOGENICITY OF A CFA α -DEFICIENT, ENTEROTOXIN α -PRODUCING <i>ESCHERICHIA COLI</i> MUTANT IN A NON-ELICITED INTESTINE EXPERIMENTAL MODEL. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section B, Microbiology</i> , 1987, 95B, 123-130.	0.1	9
189	FIELD TRIAL OF ORAL CHOLERA VACCINES IN BANGLADESH. <i>Lancet, The</i> , 1986, 328, 124-127.	13.7	345
190	Monoclonal Antibodies and Immunodetection Methods for <i>Vibrio cholerae</i> and <i>Escherichia coli</i> Enterotoxins. , 1986, , 77-97.		7
191	GM1 ELISA method for demonstration of <i>Escherichia coli</i> heat-stable enterotoxin. <i>FEMS Microbiology Letters</i> , 1985, 30, 1-6.	1.8	19
192	Vaccine Development for the Control of Cholera and Related Toxin-Induced Diarrhoeal Diseases. <i>Novartis Foundation Symposium</i> , 1985, 112, 242-270.	1.1	1
193	Cholera and the Immune Response. <i>Chemical Immunology and Allergy</i> , 1983, 33, 106-119.	1.7	0
194	Protection against Cholera in Breast-Fed Children by Antibodies in Breast Milk. <i>New England Journal of Medicine</i> , 1983, 308, 1389-1392.	27.0	334
195	Isolation of <i>Escherichia coli</i> heat-labile enterotoxin by affinity chromatography: Characterization of subunits. <i>Current Microbiology</i> , 1980, 3, 339-344.	2.2	15
196	The Nature of Protective Immunity in Cholera1. , 1980, , 171-184.		10
197	Antitoxic Cholera Immunity in Mice: Influence of Antigen Deposition on Antitoxin-Containing Cells and Protective Immunity in Different Parts of the Intestine. <i>Infection and Immunity</i> , 1980, 28, 17-23.	2.2	43
198	Immunological cross-reactivity between <i>Escherichia coli</i> heat-labile enterotoxin and cholera toxin A and B subunits. <i>Current Microbiology</i> , 1979, 2, 55-58.	2.2	24

#	ARTICLE	IF	CITATIONS
199	Identification of <i>Escherichia coli</i> heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure. <i>Current Microbiology</i> , 1978, 1, 19-23.	2.2	352
200	Mechanisms of Disease and Immunity in Cholera: A Review. <i>Journal of Infectious Diseases</i> , 1977, 136, S105-S112.	4.0	130
201	Development of improved cholera vaccine based on subunit toxoid. <i>Nature</i> , 1977, 269, 602-604.	27.8	134
202	Experimental Studies on Cholera Immunization. <i>International Archives of Allergy and Immunology</i> , 1975, 49, 434-452.	2.1	24
203	Antibodies to endotoxin from <i>Vibrio cholerae</i> measured by bactericidal and indirect hemagglutination tests. Differences in immunoglobulin classes and specificity. <i>Journal of Immunological Methods</i> , 1972, 1, 329-340.	1.4	2
204	A Radial Diffusion Agar Plaque Technique for Estimation of the Avidity of Bactericidal Antibodies against <i>Vibrio cholerae</i> . <i>Scandinavian Journal of Immunology</i> , 1972, 1, 345-350.	2.7	3
205	Immunity to <i>Vibrio cholerae</i> Infection. , 0, , 257-271.		12